Angelo Fama1,2, Melissa C Larson3, Brian K Link4, Thomas M Habermann1, Andrew L Feldman5, Timothy G Call1, Stephen M Ansell1, Mark Liebow6, Jinhua Xiang4,7, Matthew J Maurer3, Susan L Slager3, Grzegorz S Nowakowski1, Jack T Stapleton4,7, James R Cerhan3. 1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2. Ematologia, Azienda Unità Sanitaria Locale, Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 6. Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 7. Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA.
Abstract
BACKGROUND: Human pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas. METHODS: We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype. RESULTS: The overall OR for lymphoma was 2.85 (95% CI, 1.98-4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98-16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76-2.85]), Northern Europe (2.90 [.45-18.7), and the Middle East (2.51 [.87-7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63-6.62]), follicular (3.01 [1.95-4.63]), marginal zone (1.90 [1.13-3.18]), and T-cell (2.11 [1.17-3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48-25.9]) and chronic lymphocytic leukemia (1.45 [.45-4.66]) were increased but did not achieve statistical significance. CONCLUSIONS: This meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
BACKGROUND:Human pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas. METHODS: We conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype. RESULTS: The overall OR for lymphoma was 2.85 (95% CI, 1.98-4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98-16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76-2.85]), Northern Europe (2.90 [.45-18.7), and the Middle East (2.51 [.87-7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63-6.62]), follicular (3.01 [1.95-4.63]), marginal zone (1.90 [1.13-3.18]), and T-cell (2.11 [1.17-3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48-25.9]) and chronic lymphocytic leukemia (1.45 [.45-4.66]) were increased but did not achieve statistical significance. CONCLUSIONS: This meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Authors: Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels Journal: Cancer Res Date: 2014-08-12 Impact factor: 12.701
Authors: Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer Journal: J Infect Dis Date: 2014-11-25 Impact factor: 5.226
Authors: J Linnen; J Wages; Z Y Zhang-Keck; K E Fry; K Z Krawczynski; H Alter; E Koonin; M Gallagher; M Alter; S Hadziyannis; P Karayiannis; K Fung; Y Nakatsuji; J W Shih; L Young; M Piatak; C Hoover; J Fernandez; S Chen; J C Zou; T Morris; K C Hyams; S Ismay; J D Lifson; G Hess; S K Foung; H Thomas; D Bradley; H Margolis; J P Kim Journal: Science Date: 1996-01-26 Impact factor: 47.728
Authors: Jack T Stapleton; Kathryn Chaloner; Jeffrey A Martenson; Jingyang Zhang; Donna Klinzman; Jinhua Xiang; Wendy Sauter; Seema N Desai; Alan Landay Journal: PLoS One Date: 2012-11-29 Impact factor: 3.240
Authors: M A L Doan; A Roczkowsky; M Smith; G Blevins; F K H van Landeghem; B B Gelman; W G Branton; J T Stapleton; T C Hobman; C Power Journal: J Virol Date: 2021-09-15 Impact factor: 5.103
Authors: Mehdi Samadi; Vahid Salimi; Mohammad Reza Haghshenas; Seyed Mohammad Miri; Seyed Reza Mohebbi; Amir Ghaemi Journal: Virol J Date: 2022-03-09 Impact factor: 4.099